Patient-Specific Deep Reinforcement Learning for Automatic Replanning in Head-and-Neck Cancer Proton Therapy

TL;DR

This paper introduces a patient-specific deep reinforcement learning framework for automating replanning in head-and-neck proton therapy, improving plan quality amid anatomical changes and reducing manual effort.

Contribution

It presents a novel patient-specific DRL approach for IMPT replanning, trained on individual patient data and anatomical simulations, outperforming manual plans.

Findings

DRL agents improved initial plan scores significantly.

Automated replans surpassed manual plans in quality.

Clinical validation showed better tumor coverage and organ sparing.

Abstract

Anatomical changes during intensity-modulated proton therapy (IMPT) for head-and-neck cancer (HNC) can shift Bragg peaks, risking tumor underdosing and organ-at-risk overdosing. Treatment replanning is often required to maintain clinically acceptable treatment quality. However, current manual replanning processes are resource-intensive and time-consuming. We propose a patient-specific deep reinforcement learning (DRL) framework for automated IMPT replanning, with a reward-shaping mechanism based on a $150$-point plan quality score addressing competing clinical objectives. We formulate the planning process as a reinforcement learning problem where agents learn control policies to adjust optimization priorities, maximizing plan quality. Unlike population-based approaches, our framework trains agents for each patient using their planning Computed Tomography (CT) and augmented anatomies simulating anatomical changes (tumor progression and regression). This patient-specific approach leverages anatomical similarities along the treatment course, enabling effective plan adaptation. We implemented two DRL algorithms, Deep Q-Network and Proximal Policy Optimization, using dose-volume histograms (DVHs) as state representations and a $22$-dimensional action space of priority adjustments. Evaluation on eight HNC patients using actual replanning CT data showed that both agents improved initial plan scores from $120.78 \pm 17.18$ to $139.59 \pm 5.50$ (DQN) and $141.50 \pm 4.69$ (PPO), surpassing the replans manually generated by a human planner ($136.32 \pm 4.79$). Clinical validation confirms that improvements translate to better tumor coverage and OAR sparing across diverse anatomical changes. This work highlights DRL's potential in addressing geometric and dosimetric complexities of adaptive proton therapy, offering efficient offline adaptation solutions and advancing online adaptive proton therapy.